Corcept Therapeutics Is Under Siege From Every Direction

The FDA rejection

Corcept's entire investment case for the past several years has rested on relacorilant, a selective cortisol modulator designed to succeed (and eventually replace) its sole commercial product, Korlym, in treating hypercortisolism. The company filed a New Drug Application for relacorilant in March 2025, and the FDA set a target review date of December 30, 2025.

The agency rejected the application. According to the securities class action complaint filed by the DJS Law Group, the FDA had warned Corcept "on several occasions" that the clinical data supporting relacorilant was insufficient, including concerns about the design of the GRACE study (the pivotal trial). Despite those warnings, the company continued to tell investors that the product was "approaching approval" based on the "powerful evidence" it had gathered.

The rejection is not merely a regulatory setback: it is a direct challenge to the company's credibility. Corcept's Korlym faces looming patent cliffs and potential generic competition from Teva Pharmaceutical, which won a favorable ruling in a patent dispute at the appeals court level. Without relacorilant, Corcept is a one-product company whose sole revenue source is under legal threat.

The lawsuits

Two securities class action lawsuits have now been filed against Corcept, both covering the period from October 31, 2024, to December 30, 2025 (the date of the FDA rejection). The DJS Law Group filed its complaint on March 23, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Levi & Korsinsky followed on March 25 with a substantially similar filing.

The core allegation in both suits is identical: that Corcept made "false and misleading statements" about its interactions with the FDA and the likelihood of relacorilant's approval. The complaints allege that the FDA had communicated its concerns about the adequacy of the clinical program, and that the company failed to disclose those concerns to investors.

To be sure, securities class action lawsuits are filed routinely after sharp stock declines, and many are ultimately dismissed or settled for modest amounts. The mere existence of a lawsuit does not establish that fraud occurred. But the specific allegation here (that the company knew the FDA had flagged problems and continued to project confidence) is the kind of claim that, if supported by internal documents during discovery, could prove damaging.

The deadline for lead plaintiff applications is April 21, 2026.

Earnings are deteriorating

The FDA rejection arrived against a backdrop of already weakening financial performance. Corcept reported fourth-quarter 2025 revenue of $202.1 million, up 11.1 percent year over year but 18.5 percent below the analyst consensus estimate of $254.9 million. Adjusted earnings per share came in at $0.20, missing the $0.33 estimate by a wide margin. The prior quarter was not much better: Q3 revenue of $207.6 million missed estimates by a similar percentage, and EPS of $0.16 fell short of the $0.18 consensus.

For the full year, Corcept generated $761.4 million in revenue. That figure fell well below the company's own revised guidance of $800 million to $850 million, which management had set as recently as the third quarter.

The company has guided fiscal 2026 revenue to $900 million to $1 billion, implying 18 to 31 percent growth. But given the consecutive misses against its own targets, the market is treating that guidance with skepticism. H.C. Wainwright lowered its price target from $67 to $60 while maintaining a Buy rating.

Insiders are selling

William Guyer, Corcept's Chief Development Officer, sold 11,767 shares on March 20 at a weighted average price of $36.01, for total proceeds of $423,729. The sale was executed under a pre-arranged 10b5-1 trading plan adopted in November 2024, which means it was scheduled well before the current crisis. On the same day, Guyer exercised options to acquire the same number of shares at $21.65.

The insider activity is not uniformly bearish: director G. Leonard Baker Jr. recently purchased 100,000 shares, increasing his direct holdings to over 1.1 million shares. But the optics of a C-suite officer selling into a 60 percent decline are difficult to ignore, regardless of the pre-arranged nature of the transaction.

What comes next

Corcept's near-term path depends on three variables. First, whether the company can redesign or supplement the relacorilant clinical program to address the FDA's concerns and refile the NDA. The company has indicated it is pursuing relacorilant in oncology (specifically ovarian cancer), which could provide an alternative approval pathway, but that timeline is measured in years, not quarters.

Second, the Teva patent litigation. An appeals court ruling in Teva's favor on the Korlym patent dispute could open the door to generic competition for Corcept's only marketed product. The combination of a failed pipeline drug and a vulnerable franchise product is the worst-case scenario for a single-product biopharma company.

Third, the securities litigation. Discovery in the class action suits could surface internal communications about the FDA's warnings, which would either validate or undermine the fraud allegations.

At $33.82, Corcept trades at roughly 4.4 times trailing twelve-month revenue and 41 times trailing earnings. The 13 Buy ratings and median analyst target of $67 suggest the Street still sees a path to recovery. But the gap between that target and the current price reflects the depth of the uncertainty. Only time will tell whether the relacorilant setback is a delay or a dead end, but the market is pricing in the latter.